$INCY
INCYTE CORP
Runway:cash-flow +
NasdaqMarket cap: —CIK 0000879169
Upcoming catalysts
0 surfacedNo catalysts surfaced for INCY yet.
Drug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06259669 | Ruxolitinib cream | — | Recruiting | 2032-08-01 |
| NCT06615050 | Tacrolimus (Tac) | Phase 3 | Recruiting | 2031-01-17 |
| NCT04849715 | — | Phase 3 | Withdrawn | 2030-08-15 |
| NCT07441694 | — | Phase 1 | Recruiting | 2030-05-24 |
| NCT07623200 | — | Phase 3 | Not Yet Recruiting | 2029-06-15 |
| NCT07124078 | — | Phase 2 | Recruiting | 2029-01-31 |
| NCT07284849 | — | Phase 3 | Recruiting | 2028-12-29 |
| NCT04796922 | — | Phase 3 | Withdrawn | 2028-12-20 |
| NCT07214779 | INCB123667 | Phase 3 | Recruiting | 2028-11-15 |
| NCT06034002 | — | Phase 1 | Recruiting | 2028-10-29 |
| NCT06313593 | — | Phase 1 | Recruiting | 2028-10-09 |
| NCT07522073 | INCB161734 | Phase 3 | Recruiting | 2028-09-15 |
| NCT07195916 | — | Phase 1 | Recruiting | 2028-08-18 |
| NCT06821542 | — | Phase 3 | Active Not Recruiting | 2028-05-31 |
| NCT07213973 | Povorcitinib | Phase 2 | Recruiting | 2028-03-25 |
| NCT07008118 | — | Phase 1 | Recruiting | 2028-03-14 |
| NCT05936359 | — | Phase 1 | Recruiting | 2028-02-29 |
| NCT06855498 | Povorcitinib | Phase 3 | Recruiting | 2028-02-28 |
| NCT03934372 | — | Phase 2 | Recruiting | 2028-02-01 |
| NCT05919511 | Non-Interventional | — | Recruiting | 2027-10-15 |